Whistleblowers : Incentives, Disincentives, and Protection Strategies

**Solid guidance for managing whistleblower policies in light of the new Dodd-Frank Act provisions**In July 2010, President Obama signed the Dodd-Frank Wall Street Reform and Consumer Protection Act that greatly expanded whistleblower bounties in connection with violations of federal securities laws, including the Foreign Corrupt Practices Act. Discussing business protection strategies and best practices in dealing with whistleblowers, Whistleblowers will appeal to board members, executives, corporate compliance personnel, attorneys for whistleblowers and defense attorneys, as well as potential employee whistleblowers. * Case studies of GlaxoSmithKline, Pfizer and other high profile whistleblower incidences * Examines new Dodd-Frank incentives to whistleblowers * Recommends best practices for corporations in light of new whistleblowing incentives * Explores other federal and state statutory incentives to whistleblowing Timely and comprehensive, __Whistleblowers__ emphasizes the disincentives to whistleblowing, reviewing the academic studies of whistleblowers with the idea of developing best practices in working with whistleblowers. Part I The Whistleblowers and the Dodd-Frank Incentives -- -- Chapter 1 The Dramatic Expansion of Whistleblower Awards under Dodd-Frank -- 11 Whistleblower Provisions of Dodd-Frank -- 13 What Is "Original Information"? -- 14 What Are Violations of the Federal Securities Laws? -- 15 Rule 10b-5: Market Manipulation -- 19 Violating the Accounting Standards -- 20 False Financial Statements by Public Companies -- 20 Other Securities Laws -- 22 Protections for Whistleblowers -- 23 Commodity Exchange Act -- 23 Notes -- 25 -- Chapter 2 The Remarkable Story of Cheryl Eckard and the $96 Million Bounty under the False Claims Act -- 27 Who Is Cheryl Eckard? -- 27 Eckard's Post-termination Activities -- 28 Eckard's Superiors -- 29 Background Allegations -- 30 Alleged Violations -- 31 Timeline of Eckard's Alleged Activities -- 33 The Lessons of Glaxo -- 40 Notes -- 42 -- Chapter 3 The Pfizer Whistleblowers Who Collected Over $100 Million under the False Claims Act -- 45 John Kopchinski -- 46 Bextra -- 47 The Complaint -- 48 Pfizer Lessons -- 51 Notes -- 53 -- Part II Disincentives and Factors Motivating Public Disclosure -- -- Chapter 4 Disincentives to Internal Whistleblowers -- 57 Financial Disincentives -- 58 Nonfinancial Disincentives -- 59 Contractual Commitments and Fiduciary Duties -- 60 Ethics Resource Center Survey -- 61 Reinstatement as a Remedy -- 62 Empirical Study -- 65 Notes -- 67 -- Chapter 5 Women as Whistleblowers: Factors Motivating Public Whistleblowing -- 69 Sherron Watkins -- 69 Cynthia Cooper -- 71 Coleen Rowley -- 71 External Reporting by Internal Whistleblowers -- 72 Whistleblower Anonymity -- 74 Notes -- 74 -- Part III Organizational Best Practices -- -- Chapter 6 Why Should Organizations Adopt a Robust Whistleblower System? -- 79 Diminishment of Shareholder Wealth -- 80 Boards of Directors -- 81 We Were Duped! -- 82 Executive Whistleblowers -- 84 Why Independent Directors Cannot Rely Solely on Independent or Internal Auditors -- 86 Legal Standard -- 89 Caremark -- 90 Recommended Strategy -- 91 Criminal Liability of an Organization -- 92 Responsible Corporate Officer Doctrine -- 93 The Acme Markets Case -- 94 The U.S. Department of Justice Criminal Guidelines -- 96 The Disadvantages of a Robust Whistleblower System -- 97 Notes -- 98 -- Chapter 7 Establishing a Robust Whistleblower System -- 103 Problems with the Current Whistleblower System -- 104 Initial Steps -- 107 Elements of a Robust Whistleblower Policy -- 108 Independent Directors Must Be in Charge -- 109 The Whistleblower Program Must Be Independently Administered -- 111 Whistleblower Complaints Should be Investigated by Independent Counsel Reporting Directly to the Independent Directors -- 113 There Should Be No Presumption that Anonymous Complaints Are Less Deserving of Investigation -- 117 Motivations and Personality of the Whistleblower Are Not Relevant to the Truth of the Allegations -- 118 Absolute Protection of Whistleblowers' Identity Is Essential -- 119 Assess the Effectiveness of Hotlines and Provide Employee Compliance Training -- 123 Independent Counsel Should Report the Status and Results of the Investigation -- 124 Internal Whistleblowers Should Receive Meaningful Monetary Rewards -- 125 The Whistleblower Policy Must Be Communicated Effectively -- 127 There Should Be Milder Sanctions for Whistleblowers Involved in Illegal Group Activity -- 130 Retaliation Claims Should Be Independently Investigated -- 131 The Director of Corporate Compliance Should Become the Eyes and Ears of the Independent Directors -- 132 Major Dos and Don'ts for CEOs -- 134 Notes -- 135 -- Part IV Statutory Incentives and Sec Award Regulations -- -- Chapter 8 The False Claims Act: Qui Tarn Cases -- 141 What Is a False Claim? -- 142 False Claims Act Bounties -- 144 U.S. Department of Justice Memorandum -- 146 Statute of Limitations -- 149 Notes -- 150 -- Chapter 9 IRS Whistleblowers -- 153 Section 7623(b): Mandatory Whistleblower Awards -- 155 Reduction of Award Percentage -- 156 Section 7623(a): Discretionary Awards -- 157 Form 211 -- 158 IRS Whistleblowers Awards -- 159 IRS Award Determinations -- 160 Award Administrative Proceedings -- 162 Appeal to Tax Court -- 164 Duration of Process and Award Payment -- 164 Confidentiality of Whistleblower -- 165 Right to Counsel -- 165 IRS Contracts -- 165 Disqualification of U.S. Treasury Department Federal Employees -- 166 Notes -- 167 -- Chapter 10 Other Statutory Incentives and Protections for Whistleblowers -- 169 Act to Prevent Pollution from Ships -- 169 False Patent Marking Statute -- 170 U.S. Tariff Act of 1930 -- 172 State False Claims Statutes -- 173 Whistleblower Protections -- 179 Barker v. UBS -- 180 Other Statutory Whistleblower Protections -- 185 Notes -- 186 -- Chapter 11 A Step-by-Step Guide to SEC Whistleblowers Awards under Dodd-Frank -- 189 Summary -- 190 SEC Investor Protection Fund -- 194 Does the Whistleblower Need an Attorney? -- 195 Step-by-Step Guide -- 196 Determining Whether the Over $1 Million Threshold Is -- 202 Satisfied Determining the Amount of an Award -- 202 Must an Employee Comply with the Company's Internal Compliance Program? -- 204 Confidentiality -- 205 Nonwaiver of Whistleblower Rights -- 205 Appeals -- 205 Anti-retaliation Provision -- 206 Notes-- 206. Solid guidance for managing whistleblower policies in light of the new Dodd-Frank Act provisions

In July 2010, President Obama signed the Dodd-Frank Wall Street Reform and Consumer Protection Act that greatly expanded whistleblower bounties in connection with violations of federal securities laws, including the Foreign Corrupt Practices Act. Discussing business protection strategies and best practices in dealing with whistleblowers, Whistleblowers will appeal to board members, executives, corporate compliance personnel, attorneys for whistleblowers and defense attorneys, as well as potential employee whistleblowers.

• Case studies of GlaxoSmithKline, Pfizer and other high profile whistleblower incidences
• Examines new Dodd-Frank incentives to whistleblowers
• Recommends best practices for corporations in light of new whistleblowing incentives
• Explores other federal and state statutory incentives to whistleblowing

Timely and comprehensive, Whistleblowers emphasizes the disincentives to whistleblowing, reviewing the academic studies of whistleblowers with the idea of developing best practices in working with whistleblowers.

"The book will discuss business protection strategies and best practices in dealing with whistleblowers, as well as the GlaxoSmithKline, Pfizer and other high profile whistleblower cases. The book is expected to appeal to Board members, C-Suite executives, corporate compliance personnel, attorneys for whistleblowers and defense attorneys as well as all potential employee whistleblowers. The book emphasizes the disincentives to whistleblowing, and will review the academic studies of whistleblowers with the idea of developing best practices to deal with whistleblowers: Introduction. 1. Dodd-Frank Incentives to Whistleblowers 2. The Remarkable Story of Cheryl Eckard and the $96 Million Bounty 3. The Pfizer Over $100 Million Bounty Collectors 4. Other Statutory Incentives to Whistleblowing 5. Disincentives to Whistleblowers and Academic Studies of Whistleblowers 6. Best Practices in Complying with the U.S. Department of Justice Guidelines 7. Best Practices for CEOs in Dealing with Whistleblowers 8. Best Practices for Conducting Whistleblower Investigations 9. The New SEC Whistleblower Rules 10. Qui Tam Actions and Their Defense "-- Provided by publisher "The book will discuss business protection strategies and best practices in dealing with whistleblowers, as well as the GlaxoSmithKline, Pfizer and other high profile whistleblower cases. The book is expected to appeal to Board members, C-Suite executives, corporate compliance personnel, attorneys for whistleblowers and defense attorneys as well as all potential employee whistleblowers. The book emphasizes the disincentives to whistleblowing, and will review the academic studies of whistleblowers with the idea of developing best practices to deal with whistleblowers: Introduction. 1. Dodd-Frank Incentives to Whistleblowers 2. The Remarkable Story of Cheryl Eckard and the $96 Million Bounty 3.The Pfizer Over $100 Million Bounty Collectors 4.Other Statutory Incentives to Whistleblowing 5.Disincentives to Whistleblowers and Academic Studies of Whistleblowers 6.Best Practices in Complying with the U. S. Department of Justice Guidelines 7.Best Practices for CEOs in Dealing with Whistleblowers 8.Best Practices for Conducting Whistleblower Investigations 9.The New SEC Whistleblower Rules 10.Qui Tam Actions and Their Defense "--